X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2454) 2454
pyrrolidines - therapeutic use (2010) 2010
male (1920) 1920
animals (1472) 1472
female (1343) 1343
pyrrolidines - pharmacology (1080) 1080
middle aged (912) 912
adult (813) 813
pharmacology & pharmacy (800) 800
rats (724) 724
aged (632) 632
pyrrolidines - administration & dosage (496) 496
mice (489) 489
pyrrolidines - adverse effects (444) 444
adamantane - analogs & derivatives (417) 417
dose-response relationship, drug (373) 373
treatment outcome (347) 347
diabetes mellitus, type 2 - drug therapy (337) 337
double-blind method (334) 334
pyrrolidines - chemistry (332) 332
adamantane - therapeutic use (308) 308
neurosciences (297) 297
nitriles - therapeutic use (297) 297
clinical trials as topic (268) 268
rats, sprague-dawley (268) 268
adolescent (260) 260
pyrrolidines (255) 255
pyrrolidines - pharmacokinetics (253) 253
hypoglycemic agents - therapeutic use (248) 248
time factors (237) 237
disease models, animal (234) 234
dipeptidyl-peptidase iv inhibitors - therapeutic use (231) 231
analysis (230) 230
endocrinology & metabolism (226) 226
chemistry, medicinal (213) 213
vildagliptin (208) 208
type 2 diabetes (193) 193
pyrrolidine dithiocarbamate (191) 191
administration, oral (190) 190
drug therapy, combination (183) 183
biochemistry & molecular biology (177) 177
expression (177) 177
research (172) 172
rats, wistar (170) 170
oncology (167) 167
care and treatment (158) 158
drug therapy (157) 157
sulfonamides - therapeutic use (155) 155
activation (154) 154
psychiatry (154) 154
inflammation (146) 146
apoptosis (145) 145
diabetes (145) 145
thiocarbamates - pharmacology (144) 144
double-blind (143) 143
pharmacology/toxicology (141) 141
inhibition (140) 140
rodents (140) 140
pyrrolidines - metabolism (138) 138
clinical neurology (137) 137
efficacy (136) 136
diabetes mellitus, type 2 - blood (125) 125
medicine, research & experimental (124) 124
structure-activity relationship (123) 123
medicine & public health (122) 122
pharmacokinetics (122) 122
adamantane - adverse effects (121) 121
glucagon-like peptide-1 (121) 121
health aspects (121) 121
oxidative stress (120) 120
pyrrolidine (120) 120
research article (119) 119
chemistry, multidisciplinary (118) 118
indoles - therapeutic use (118) 118
aged, 80 and over (117) 117
drugs (117) 117
blood glucose - metabolism (115) 115
pharmacology (115) 115
adamantane - pharmacology (114) 114
nitriles - adverse effects (113) 113
nitriles - pharmacology (112) 112
proteins (111) 111
glucose (109) 109
cancer (108) 108
biomedicine (107) 107
nf-kappa b - metabolism (106) 106
cardiac & cardiovascular systems (104) 104
cell line, tumor (104) 104
safety (104) 104
cells (102) 102
internal medicine (102) 102
anti-arrhythmia agents - therapeutic use (101) 101
medicine, general & internal (101) 101
molecular structure (101) 101
thiocarbamates - therapeutic use (101) 101
migraine disorders - drug therapy (100) 100
nf-kappa b - antagonists & inhibitors (100) 100
mice, inbred c57bl (99) 99
rat (99) 99
toxicology (99) 99
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3319) 3319
French (166) 166
German (97) 97
Italian (72) 72
Japanese (58) 58
Russian (38) 38
Spanish (32) 32
Chinese (13) 13
Polish (11) 11
Portuguese (9) 9
Hungarian (6) 6
Norwegian (4) 4
Swedish (4) 4
Czech (3) 3
Dutch (3) 3
Finnish (3) 3
Slovak (2) 2
Croatian (1) 1
Danish (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 496 - 503
Summary In March, 2010, a group of breast cancer experts met to develop a consensus statement on breast cancer prevention, with a focus on medical and therapeutic interventions... 
Hematology, Oncology and Palliative Medicine | ZOLEDRONIC ACID | SURGICAL ADJUVANT BREAST | ONCOLOGY | STATIN USE | LOW-DOSE TAMOXIFEN | RANDOMIZED-TRIAL | FOLLOW-UP | RISK | BOWEL PROJECT | POSTMENOPAUSAL WOMEN | GENOME-WIDE ASSOCIATION | Thiophenes - therapeutic use | Metformin - therapeutic use | Raloxifene Hydrochloride - therapeutic use | Humans | Selective Estrogen Receptor Modulators - adverse effects | Tetrahydronaphthalenes - therapeutic use | Pyrrolidines - therapeutic use | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Estrogen Receptor Modulators - therapeutic use | Retinoids - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Female | Aromatase Inhibitors - therapeutic use | Estrogen Receptor Modulators - adverse effects | Anticarcinogenic Agents - therapeutic use | Triazoles - therapeutic use | Premenopause | Anastrozole | Consensus Development Conferences as Topic | Breast Neoplasms - prevention & control | Fenretinide - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Tamoxifen - therapeutic use | Androstadienes - therapeutic use | Expert Testimony | Norpregnenes - therapeutic use | Nitriles - therapeutic use | COX-2 inhibitors | Care and treatment | Aspirin | Oncology, Experimental | Menopause | Phosphonates | Breast cancer | Retinoids | Research | Tamoxifen | Prevention | Analysis | Health aspects | Cancer
Journal Article
Best Practice & Research: Clinical Endocrinology & Metabolism, ISSN 1521-690X, 2007, Volume 21, Issue 4, pp. 517 - 533
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1... 
Endocrinology & Metabolism | treatment | dipeptidyl peptidase 4 | sitagliptin | type-2 diabetes | vildagliptin | glucagon-like peptide-1 | GLYCEMIC CONTROL | DIPEPTIDYL-PEPTIDASE-IV | INSULIN-SECRETION | IMPROVED GLUCOSE-TOLERANCE | BETA-CELL FUNCTION | METFORMIN-TREATED PATIENTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | PLASMA-GLUCOSE | 7-36 AMIDE | Triazoles - adverse effects | Metformin - therapeutic use | Humans | Body Weight - drug effects | Pyrrolidines - adverse effects | Substrate Specificity | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Hypoglycemia - chemically induced | Protease Inhibitors - therapeutic use | Insulin Secretion | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Pioglitazone | Insulin - metabolism | Animals | Dipeptidyl-Peptidase IV Inhibitors | Lipid Metabolism - drug effects | Pyrazines - adverse effects | Glucagon - metabolism | Vildagliptin | Glucagon-Like Peptide 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Clinical Medicine | Other Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Adamantane/adverse effects Adamantane/analogs & derivatives Adamantane/therapeutic use Animals Antigens | Annan klinisk medicin | Combination Glucagon/secretion Glucagon-Like Peptide 1/antagonists & inhibitors Glucagon-Like Peptide 1/physiology Humans Hypoglycemia/chemically induced Hypoglycemic Agents/therapeutic use Insulin/secretion Insulin/therapeutic use Lipid Metabolism/drug effects Metformin/therapeutic use Nitriles/adverse effects Nitriles/therapeutic use Protease Inhibitors/therapeutic use Pyrazines/adverse effects Pyrazines/therapeutic use Pyrrolidines/adverse effects Pyrrolidines/therapeutic use Substrate Specificity Thiazolidinediones/therapeutic use Triazoles/adverse effects Triazoles/therapeutic use | Type 2/drug therapy Drug Therapy | Klinisk medicin | CD26/antagonists & inhibitors Body Weight/drug effects Diabetes Mellitus
Journal Article
Diabetes and Metabolism, ISSN 1262-3636, 2012, Volume 38, Issue 2, pp. 89 - 101
Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering... 
Internal Medicine | Endocrinology & Metabolism | Linagliptine | Sitagliptin | Type 2 diabetes mellitus | Review | Clinical trial-DPP-4 inhibitor | Vildagliptine | Saxagliptine | Diabète de type 2 | Inhibiteur de la DPP-4 | Alogliptin | Sitagliptine | Linagliptin | Vildagliptin | Alogliptine | Revue générale | Essai clinique | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | INITIAL COMBINATION THERAPY | RENAL IMPAIRMENT | DRUG-NAIVE PATIENTS | ADD-ON THERAPY | IMPROVES GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | METFORMIN THERAPY | WEIGHT-GAIN | ELDERLY-PATIENTS | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Glycated Hemoglobin A - drug effects | Male | Pyrazines - therapeutic use | Pyrrolidines - therapeutic use | Adamantane - therapeutic use | Female | Weight Gain - drug effects | Purines - therapeutic use | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Uracil - therapeutic use | Clinical Trials as Topic | Diabetes Mellitus, Type 2 - blood | Piperidines - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - drug therapy | Nitriles - therapeutic use | Uracil - analogs & derivatives
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 17, pp. 1612 - 1620
.... The results indicate that among these patients, the use of VX-445-tezacaftor-ivacaftor to target Phe508del CFTR protein resulted in increased CFTR function in vitro... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | TEZACAFTOR-IVACAFTOR | CFTR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - administration & dosage | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Chlorides - metabolism | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Pyrazoles - administration & dosage | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Pyridines - pharmacology | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Statistical analysis | Writers | Epithelial cells | Chloride transport | Recovery of function | Patients | Design | Proteins | Genotype & phenotype | Chloride | Collaboration | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Pharmaceuticals
Journal Article
Seminars in Nephrology, ISSN 0270-9295, 2016, Volume 36, Issue 6, pp. 436 - 447
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 17, pp. 1599 - 1611
... Phe508del alleles or a gating or residual-function CFTR mutation), small-molecule CFTR modulators provide therapeutic benefit by restoring CFTR activity. 5 However... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Conductance | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 06/2012, Volume 156, Issue 12, pp. 861 - 874
Background: Urinary incontinence (UI) in women adversely affects quality of life. Purpose: To conduct a systematic literature review of drugs for urgency UI in... 
OVERACTIVE BLADDER SYNDROME | MEDICINE, GENERAL & INTERNAL | DAILY TROSPIUM CHLORIDE | ONCE-DAILY FORMULATION | SELECTIVE RECEPTOR ANTAGONIST | QUALITY-OF-LIFE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | EXTENDED-RELEASE TOLTERODINE | ANTIMUSCARINIC AGENT SOLIFENACIN | PATIENT-REPORTED OUTCOMES | Cresols - therapeutic use | Benzilates | Humans | Muscarinic Antagonists - adverse effects | Cresols - adverse effects | Solifenacin Succinate | Pyrrolidines - adverse effects | Muscarinic Antagonists - therapeutic use | Phenylpropanolamine - adverse effects | Phenylpropanolamine - therapeutic use | Pyrrolidines - therapeutic use | Benzhydryl Compounds - adverse effects | Comparative Effectiveness Research | Quinuclidines - therapeutic use | Nortropanes - adverse effects | Mandelic Acids - therapeutic use | Tolterodine Tartrate | Female | Nortropanes - therapeutic use | Mandelic Acids - adverse effects | Benzhydryl Compounds - therapeutic use | Quinuclidines - adverse effects | Benzofurans - therapeutic use | Tetrahydroisoquinolines - adverse effects | Tetrahydroisoquinolines - therapeutic use | Benzofurans - adverse effects | Randomized Controlled Trials as Topic | Urinary Incontinence - drug therapy | Quality of Life | Urinary incontinence | Research | Demographic aspects | Drug therapy | Patient outcomes
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 05/2017, Volume 2017, Issue 5, p. CD012204
Background The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether... 
Diabetes Type 2 | Adamantane | Peptides | Glucagon‐Like Peptide 1 | Dipeptidyl‐Peptidase IV Inhibitors | Exenatide | Glucose Intolerance | Hypoglycemic Agents | Glycated Hemoglobin A | Pyrrolidines | Nitriles | Diabetes Mellitus, Type 2 | Diabetes mellitus and Related Disorders | Endocrine & metabolic | Fasting | Related Disorders | Risk Factors | Blood Glucose | Randomized Controlled Trials as Topic | Incretins | Venoms | Vildagliptin | Metformin | Diabetes | Medicine General & Introductory Medical Sciences | Liraglutide | LIRAGLUTIDE 3.0 MG | RANDOMIZED CONTROLLED-TRIALS | MEDICINE, GENERAL & INTERNAL | VISCERAL FAT DISTRIBUTION | EXENATIDE VS. METFORMIN | DM COMPARING ALOGLIPTIN | IMPAIRED GLUCOSE-TOLERANCE | ACUTE CORONARY SYNDROMES | CLINICALLY SOUND TREATMENT | BASE-LINE IMBALANCE | BETA-CELL FUNCTION | Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Glucagon-Like Peptide 1 - analogs & derivatives | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Diabetes Mellitus, Type 2 - prevention & control | Pyrrolidines - therapeutic use | Liraglutide - therapeutic use | Venoms - therapeutic use | Adamantane - therapeutic use | Incretins - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - complications | Peptides - therapeutic use | Adamantane - analogs & derivatives | Nitriles - therapeutic use
Journal Article